Meet the Management Team
Callion Pharma has decades of formulation and clinical research experience helping patients overcome micronutrient malabsorption.
Konstantinos (Gus) Papas MD, MPH
President, Callion Pharma
Dr. Papas is a board certified internal medicine physician with an interest in fat-soluble vitamin malabsorption. He received his medical degree from the University of North Carolina at Chapel Hill and completed his internal medicine residency at Stanford. As the Vice President of Medical Affairs at Yasoo Health, he developed nutritional products to overcome micronutrient deficiency. He designed, executed and supervised clinical studies that validated the clinical efficacy of these products resulting in the published manuscripts documented below. He has presented his findings at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, the North American Cystic Fibrosis Conference, American Society for Metabolic & Bariatric Surgery and multiple cystic fibrosis clinics.
Papas K, Kalbfleisch J, Mohon R. Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing patients. Dig Dis Sci. 2007 Feb;52(2):347-52.
Papas KA, Sontag MK, Pardee C, Sokol RJ, Sagel SD, Accurso FJ, Wagener JS. A pilot study on the safety and efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis. J Cyst Fibros. 2007 Jun 12.
Sagel, SD, Sontag MK, Anthony MM, Emmett P, Papas KA. Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis. J Cyst Fibros. 2011;10:31-36.
Peterson LA, Cheskin LJ, Furtado M, Papas K, Schweitzer MA, Magnuson TH, Steele KE. Malnutrition in Bariatric Surgery Candidates: Multiple Micronutrient Deficiencies Prior to Surgery. Obes Surg. 2015 Aug 22.
Development and Operations Team
The Callion Pharma team combines expertise in the design, development and commercialization of disease specific products based on science and clinical evidence. This experience includes feasibility, scale-up and troubleshooting related to commercial production of pharmaceutical and dietary supplement liquid and solid dosage forms. Members have experience with researching fitness-for-use criteria of materials that enhanced the absorption of poorly bioavailable pharmaceutical actives as well as formulation techniques related to targeted intestinal drug delivery. The team has a proven record of obtaining research funding, including the National Institutes of Health and the Cystic Fibrosis Foundation and participating in clinical trials with leading universities.